LMRI · Lumexa Imaging Holdings, Inc. Common Stock

Lumexa Imaging delivered Q1 2026 results showing modest revenue growth of 3.1% to $252.5 million, driven by 1.3% higher consolidated procedures and a shift toward higher-margin advanced imaging, which grew 6.8% YoY and comprised 31.1% of total procedures (up 170bps). System-wide advanced procedures rose 6.9%, with same-center advanced volumes up 5.6% reflecting strong organic demand. Despite flat Adjusted EBITDA at $51.2 million (20.3% margin), profitability improved markedly with net income of $1.7 million versus a prior-year loss, aided by lower interest expense ($16.3 million vs. $29.8 million) likely from debt refinancing or paydown. CEO Caitlin Zulla highlighted execution on strategic priorities including same-center growth, de novo expansions (on track for 8-10 additions), and advanced imaging focus, plus announcing four new centers (two tuck-ins, two de novos). The company reiterated FY2026 guidance amid public company costs of ~$7 million, signaling confidence in sustained growth in a large addressable market with demand tailwinds. Balance sheet remains solid with $51.2 million cash, though operating cash flow softened to $2.9 million from working capital changes. Investors should note ongoing investments in technology and M&A integration, as reflected in adjustments.